.png){kind=icon}
Qing Yi
H-index:62
Citation Count:1.3万
Views:0
Biography
A medical immunologist with over 30 years of experience as a highly funded and well published investigator. Internationally recognized as a leading authority in tumor immunology and cancer immunotherapy, with a particular focus on multiple myeloma and related malignancies. Since arriving in the United States in 1998, the scholar has secured an exceptional record of extramural funding as Principal Investigator. Prior to current role as Associate Director of the Houston Methodist Cancer Center, held faculty appointments at the Lerner Research Institute at the Cleveland Clinic, MD Anderson Cancer Center, University of Arkansas for Medical Sciences, and the Karolinska Hospital and Institute, Sweden. Recent research focuses on developing novel therapeutic monoclonal antibodies for myeloma and other cancers, identifying T-cell subsets that have potent anti-tumor effects after adoptive transfer, and identifying tumor microenvironment components that induce tumor drug resistance.
Education
1993.01 – 1995.12
Karolinska Institutet Postdoctoral Fellowship Molecular Medicine
1990.01 – 1993.12
Karolinska Institutet PhD Medical Sciences
1983.01 – 1986.12
Sun Yat-Sen University MMed Medicine
1978.01 – 1983.12
Jiangxi Medical College, Jiangxi, P.R. China MD Medicine
Work Experience
2019.10 – 至今
Weill Cornell Medicine
Professor of Cancer Biology in Medicine
Honors & Awards
- Presidential Award - Excellence in Education（2023）
- Presidential Award - High Impact Publication Honoree（2025）
- Presidential Award - Peer Reviewed Publication（2025）
- Presidential Award - Peer Reviewed Publication（2021）
Activating RARβ to overcome immunomodulatory drug resistance in t(4;14) human myeloma
通过激活RARβ克服t(4;14)人类骨髓瘤的免疫调节药物耐药性
Leukemia
IF13.4
NHE6-driven endosome-autophagy axis confers proteasome inhibitor resistance in multiple myeloma
NHE6驱动的内体-自噬轴赋予多发性骨髓瘤蛋白酶体抑制剂耐药性
Drug Resistance Updates
IF21.7
T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2+ solid and hematologic cancers
针对Dickkopf-1-A2复合物的工程化T细胞可用于治疗HLA-A2阳性的实体瘤和血液系统癌症
Nature Communications
IF15.7
Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans
黑人美国人和白人美国人在多发性骨髓瘤患者适当匹配时的生存率相同
Blood Cancer Journal
IF11.6
Case Report: A case of first-line treatment for rare ROS1 fusion mutation lung adenocarcinoma with entrectinib
1例entrectinib一线治疗罕见ROS1融合突变肺腺癌的病例报告
Table tennis coaching system based on a multimodal large language model with a table tennis knowledge base
基于多模态大型语言模型和乒乓球知识库的乒乓球训练系统
PLOS ONE
IF2.6
A guideline on the molecular ecosystem regulating ferroptosis
调控铁死亡的分子生态系统指南
NATURE CELL BIOLOGY
IF19.1
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
双特异性BCMA/CD24 car-t细胞控制多发性骨髓瘤的生长
NATURE COMMUNICATIONS
IF15.7
ALCAM regulates multiple myeloma chemoresistant side population
ALCAM调节多发性骨髓瘤化疗耐药侧群
CELL DEATH & DISEASE
IF9.6
CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability
CD36-mediated铁死亡抑制肿瘤内CD8 T细胞效应功能并损害其抗肿瘤能力
CELL METABOLISM
IF30.9
